| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.14 | 0.0008 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0008 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.098 | 0.003 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.091 | 0.004 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.004 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |